




RealRate

PHARMACEUTICAL 2021

Galectin Therapeutics INC
Rank 180 of 394



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Galectin Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Galectin Therapeutics INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 70% points. The greatest weakness of Galectin Therapeutics INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 45% points.

The company's Economic Capital Ratio, given in the ranking table, is 280%, being 24% points above the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	29,465
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,399
Liabilities, Non-Current	8.0
Other Assets	135
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-21
Other Revenues	0
Property and Equipment	0
Research and Development	17,976
Selling, General and Administrative Expense	5,468

Output Variable	Value in 1000 USD
Assets	29,600
Liabilities	5,407
Expenses	23,444
Revenues	0
Stockholders Equity	24,193
Net Income	-23,465
Comprehensive Net Income	-23,465
BaseVar	29,236
ECR before LimitedLiability	167%
Economic Capital Ratio	280%